BVS Strangle Strategy

BVS (Bioventus Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system.

BVS (Bioventus Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $942.7M, a trailing P/E of 17.34, a beta of 0.65 versus the broader market, a 52-week range of 6.255-15.893, average daily share volume of 666K, a public-listing history dating back to 2021, approximately 950 full-time employees. These structural characteristics shape how BVS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.65 indicates BVS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on BVS?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

BVS snapshot

As of August 14, 2026, spot at $14.34, ATM IV 65.20%, IV rank 14.63%, expected move 18.69%. The strangle on BVS below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this strangle structure on BVS specifically: BVS IV at 65.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a BVS strangle, with a market-implied 1-standard-deviation move of approximately 18.69% (roughly $2.68 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BVS expiries trade a higher absolute premium for lower per-day decay. Position sizing on BVS should anchor to the underlying notional of $14.34 per share and to the trader's directional view on BVS stock.

BVS strangle setup

The BVS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BVS at $14.34 on that close, the first option leg uses a $15.06 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BVS chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BVS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$15.06	N/A
Buy 1	Put	$13.62	N/A

BVS strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

BVS strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on BVS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on BVS

Strangles on BVS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BVS chain.

BVS thesis for this strangle

The market-implied 1-standard-deviation range for BVS extends from approximately $11.66 on the downside to $17.02 on the upside. A BVS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current BVS IV rank near 14.63% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BVS at 65.20%. As a Healthcare name, BVS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BVS-specific events.

BVS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BVS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BVS alongside the broader basket even when BVS-specific fundamentals are unchanged. Always rebuild the position from current BVS chain quotes before placing a trade.

Frequently asked questions

What is a strangle on BVS?: A strangle on BVS is the strangle strategy applied to BVS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With BVS stock at $14.34 on the most recent close, the strikes shown on this page are snapped to the nearest listed BVS chain strike and the premiums come straight from that session's bid/ask midpoint.
How are BVS strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BVS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 65.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a BVS strangle?: The breakeven for the BVS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The BVS market-implied 1-standard-deviation expected move in the same options snapshot is approximately 18.69%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on BVS?: Strangles on BVS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BVS chain.
How does current BVS implied volatility affect this strangle?: BVS ATM IV is at 65.20% with IV rank near 14.63%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.